Get the latest news, insights, and market updates on ABOS (Acumen Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive experti Nov 10, 2025 - $ABOS
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report third quarter 2025 financial results on Wednesday, November 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a busin Nov 5, 2025 - $ABOS
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, Nov. 11, 2025, at 4:40 p.m. ET. The live webcasts may be accessed under the Investors tab on www.acumenpharm.com and will be a Nov 4, 2025 - $ABOS
Uncovering Opportunities: Beauty Health Among 3 Promising Penny Stocks
As major U.S. stock indexes reach new highs, driven by solid corporate earnings and potential interest rate cuts, investors are increasingly looking beyond the giants of Wall Street for opportunities. Penny stocks—often representing smaller or newer companies—continue to attract attention for their potential to offer both affordability and growth. Despite being an older term, these stocks remain relevant as they can provide a unique blend of financial strength and growth prospects when... Oct 29, 2025 - $ABOS
Promising Penny Stocks To Watch In September 2025
As September 2025 unfolds, major stock indexes in the United States have rebounded, closing higher despite looming concerns over a potential government shutdown. In such a climate, investors often look for opportunities that might not be immediately apparent within the mainstream markets. Penny stocks—though an older term—still represent a niche area of investment where smaller or newer companies can offer unique growth prospects. By focusing on those with strong financials, investors may... Sep 30, 2025 - $ABOS
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences. Citi’s 2025 Biopharma Back to School Conference Date/Time: Fireside chat on Tuesday, September 2, 2025 at 3:15 p.m. ET Cantor Global Healthcare C Aug 26, 2025 - $ABOS
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Expect decision to advance an oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026 Cash, cash equivalents and marketable securities of $166.2 million as of June 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET Aug 12, 2025 - $ABOS
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report second quarter 2025 financial results on Tuesday, August 12, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business Aug 5, 2025 - $ABOS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple